References
- BerensonJRLichtensteinAPorterL1996Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myelomaN Engl J Med334488938559201
- BerensonJRRajdevLBroderM2007Bone complications in multiple myelomaCancer Biol Ther51082516969119
- de LemosMLTaylorSCBarnettJB2007Renal safety of one hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based databaseJ Oncol Pharm Prac121939
- DesikanRVekslerYRazaS2002Nephrotic proteinuria associated with high-dose pamidronate in multiple myelomaBr J Haematol119496912406092
- Janssen van DoornKNeynsBVan der NiepenP2001Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastasesNephron89467811721169
- KanisJAMcCloskeyEVTaubeT1991Rationale for the use of bisphosphonates in bone metastasesBone12138
- KellihanMJManginoPD1992PamidronateAnn Pharmacother26126291421653
- KyleRAYeeGCSomerfieldMR2007American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myelomaJ Clin Oncol2524647217515569
- LacyMQDispenzieriAGertzMA2006Mayo clinic consensus statement for the use of bisphosphonates in multiple myelomaMayo Clin Proc8110475316901028
- LeyvrazSHessUFleschG1992Pharmacokinetics of pamidronate in patients with bone metastasesJ Nat Cancer Inst84788921573666
- LockridgeLPapacRJPerazellaMA2002Pamidronate-associated nephrotoxicity in a patient with Lagerhans’s histiocytosisAm J Kidney Dis40E212087588
- MarkowitzGSAppelGBFinePL2001Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronateJ Am Soc Nephrol1211647211373339
- MarkowitzGSFinePLD’AgatiVD2002Nephrotic syndrome after treatment with pamidronateAm J Kidney Dis3911182211979358
- MehrotraBRuggieroS2006Bisphosphonate complications including osteonecrosis of the jawHematology, American Society of Hematology, Education Program Book35660
- MiglioratiCASiegelMAEltingLS2006Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatmentLancet Oncol75081416750501
- Nussbaum YoungerJSrVandepolCj1993Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosagesAm J Med952973048368227
- RosenLSGordonDKaminskiM2001Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trialCancer J73778711693896
- TanvetyanonTStiffPJ2006Management of the adverse effects associated with intravenous bisphosphonatesAnn Oncol17689790716547070
- TyrellCJCollinsonMMadsenEL1994Intravenous pamidronate: infusion rate and safetyAnn Oncol527298204528
- YehHSBerensonJR2006Treatment for myeloma bone diseaseClinical Cancer Research12627984